1. Home
  2. SPFI vs CSTL Comparison

SPFI vs CSTL Comparison

Compare SPFI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo South Plains Financial Inc.

SPFI

South Plains Financial Inc.

HOLD

Current Price

$44.75

Market Cap

794.2M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$28.82

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPFI
CSTL
Founded
1941
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
794.2M
722.8M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
SPFI
CSTL
Price
$44.75
$28.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$46.00
$45.50
AVG Volume (30 Days)
144.1K
290.0K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
1.68%
N/A
EPS Growth
17.81
N/A
EPS
0.85
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$22.65
$2.42
Revenue Next Year
$9.40
$12.69
P/E Ratio
$52.56
N/A
Revenue Growth
N/A
3.66
52 Week Low
$35.34
$14.59
52 Week High
$46.94
$44.28

Technical Indicators

Market Signals
Indicator
SPFI
CSTL
Relative Strength Index (RSI) 55.53 75.45
Support Level $39.06 $22.67
Resistance Level $44.48 $34.97
Average True Range (ATR) 1.37 1.31
MACD 0.02 0.33
Stochastic Oscillator 48.38 84.88

Price Performance

Historical Comparison
SPFI
CSTL

About SPFI South Plains Financial Inc.

South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: